Evogene, Ltd. - נכסים נקיים למניה בודדת EVGN

A high scientific barrier to entry and patent protection of algorithms reliably shield the Evogene Ltd. (EVGN) business from competitors. The book value per share assessment demonstrates capital dynamics, with the metric currently standing at -0.24. The AI platform licensing model for pharma behemoths ensures high margins and a stable cash flow. Growing demand from global agricultural holdings for R&D cost optimization opens new development prospects.

Investors utilize this metric to determine the intrinsic value of a business via the ratio of equity minus liabilities to the number of shares. In the case of Evogene Ltd. (EVGN), this base reflects the capitalization of intellectual property rights for AI breeding platforms, which allows the book value per share on GURU.Markets to assess the real value of the company's high-tech assets regardless of market volatility.